Protein buffering of aneuploidy is driven by coordinated factors identified through machine learning

Area of Science:

• Oncology
• Molecular Biology
• Genomics

Background:

• Aneuploidy, common in cancer, changes chromosome copy numbers and protein levels.
• Protein dosage compensation mechanisms in aneuploid cells are largely unknown.
• The adaptive advantage and therapeutic relevance of protein dosage compensation are unexplored.

Purpose of the Study:

• To quantify protein dosage buffering in cancer.
• To identify molecular factors predicting protein dosage compensation.
• To explore the role of protein dosage compensation in cancer progression and drug resistance.

Main Methods:

• Developed a novel method to quantify protein dosage buffering.
• Utilized multifactorial machine learning models.
• Analyzed cancer samples to assess buffering variability.

Main Results:

• Protein dosage compensation is widespread but variable in cancer.
• Gene dependency, protein complex participation, haploinsufficiency, and mRNA decay predict buffering.
• Higher buffering correlates with reduced proteotoxic stress and increased drug resistance.

Conclusions:

• Protein dosage compensation is a crucial regulatory mechanism in aneuploid cancers.
• Protein dosage compensation influences oncogenic potential.
• Protein dosage compensation has therapeutic potential for aneuploid cancers.